compound semaglutide fda approved Novo asks to prevent compounders from making GLP-1 knockoffs Compounded "semaglutide" is not FDA-approved

In a study of more than 240,000 people, heavier individuals were significantly more likely to form stones than lean ones.[3] The reason is biochemical: obesity and insulin resistance push the kidney to excrete more calcium, oxalate, and uric acid, and they make the urine more acidic close to a perfect recipe for stone crystals

, : 22.5% (SURMOUNT-1 , 72) : 14.9% (STEP-1 , 68) ,

Retatrutide: The highest weight-loss numbers are currently reported

For those considering GLP-1 therapy who have a history of depression , discuss this openly with your prescriber

Over 612 months, average total weight loss ranges from 1522% of starting body weight depending on the medication and individual factors

doi: 10.1016/S2213-8587(21)00203-5